BioSpace News Archive

Vectorious Medical Technologies Ltd., an innovator in implantable hemodynamic monitoring in heart failure (HF), today announced results of VECTOR-HF I, a first-in-man clinical study demonstrating the robust safety, ease of use, and accuracy of its pioneering V-LAP novel wireless system.

Tenax Therapeutics, Inc. today announced the successful completion of its comparative pharmacokinetic study of TNX-201, for the treatment of pulmonary arterial hypertension (“PAH”).

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, President and Chief Executive Officer , of Ceapro, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL.

Micro-Tech Endoscopy USA, the U.S. subsidiary of the global medical device company Micro-Tech (Nanjing) Co. Ltd, which develops and supplies diagnostic and therapeutic devices in the gastroenterology space, has announced a business partnership with Wision A.I., a startup in the field of artificial intelligence-assisted diagnostics for optical medical imaging.

AbbVie (NYSE: ABBV) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.*

The shareholders of Median Technologies (ALMDT:PA) are invited to participate at the Shareholders’ Ordinary and Extraordinary General Meeting which will be held on Tuesday June 14, 2022, at 5:00 PM at PDGB, 174 avenue Victor Hugo – 75116 Paris.

Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced the hiring of Paul Friel as chief commercial officer.

Rising number of complex surgical procedures performed and increasing technological advancements in surgical imaging systems are key factors driving market revenue growth

Geneoscopy Inc., today announced findings from an early cost-effectiveness modeling study that aimed to assess the total costs and health outcomes associated with the use of an investigational RNA-FIT biomarker panel versus multi-target stool DNA (mt-sDNA), fecal immunochemical test (FIT), and colonoscopy alone for the screening of colorectal cancer (CRC).

Rising awareness about therapeutic potential of stem cells, rapid advancements in stem cell preservation and storage technologies, and increasing burden of chronic diseases are key factors driving market growth